<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10020438</article-id><article-id pub-id-type="pmcid-ver">PMC10020438.1</article-id><article-id pub-id-type="pmcaid">10020438</article-id><article-id pub-id-type="pmcaiid">10020438</article-id><article-id pub-id-type="pmid">36928441</article-id><article-id pub-id-type="doi">10.1038/s41598-023-31256-w</article-id><article-id pub-id-type="publisher-id">31256</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Non-alcoholic fatty liver disease is associated with decreased bone mineral density in upper Egyptian patients</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8339-6757</contrib-id><name name-style="western"><surname>Hassan</surname><given-names initials="AM">Amro M.</given-names></name><address><email>amrelgatet2003@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Haridy</surname><given-names initials="MA">Mustafa Ahmed</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shoaeir</surname><given-names initials="MZ">Mohamed Z.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abdel-Aziz</surname><given-names initials="TM">Tarek M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Qura</surname><given-names initials="MK">Mohamed Khairy</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kenawy</surname><given-names initials="EM">Eglal M.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mansour</surname><given-names initials="TMM">Tarek Mohamed M.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Salaheldin Elsayed</surname><given-names initials="S">Sameh</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ali</surname><given-names initials="WE">Wael Esmat</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abdelmeguid</surname><given-names initials="MM">Mona Mohamed</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0204-4715</contrib-id><name name-style="western"><surname>Abdel-Gawad</surname><given-names initials="M">Muhammad</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.411303.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2155 6022</institution-id><institution>Hepatology, Gastroenterology and Infectious Diseases Department, Faculty of Medicine, </institution><institution>Al-Azhar University, </institution></institution-wrap>Assiut, Egypt </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.411303.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2155 6022</institution-id><institution>Rheumatology and Rehabilitation Department, Faculty of Medicine, </institution><institution>Al-Azhar University, </institution></institution-wrap>Assiut, Egypt </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.411303.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2155 6022</institution-id><institution>Internal Medicine Department, Faculty of Medicine, </institution><institution>Al-Azhar University, </institution></institution-wrap>Assiut, Egypt </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.411303.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2155 6022</institution-id><institution>Radiodiagnosis Department, Faculty of Medicine, </institution><institution>Al-Azhar University, </institution></institution-wrap>Assiut, Egypt </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.411303.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2155 6022</institution-id><institution>Medical Biochemistry Department, Faculty of Medicine, </institution><institution>Al-Azhar University, </institution></institution-wrap>Assiut, Egypt </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.411303.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2155 6022</institution-id><institution>Clinical Pathology Department, Faculty of Medicine, </institution><institution>Al-Azhar University, </institution></institution-wrap>Assiut, Egypt </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>13</volume><issue-id pub-id-type="pmc-issue-id">425018</issue-id><elocation-id>4353</elocation-id><history><date date-type="received"><day>27</day><month>9</month><year>2022</year></date><date date-type="accepted"><day>8</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>18</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-04 23:25:13.090"><day>04</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2023_Article_31256.pdf"/><abstract id="Abs1"><p id="Par1">Nonalcoholic fatty liver disease (NAFLD) has been linked with a number of extra hepatic diseases and could be a potential risk factor of decreasing bone mineral density. To determine whether Upper Egyptian patients with NAFLD are at risk of developing osteoporosis. Cross sectional study was done on a total 100 individuals; 50 patients diagnosed with NAFLD (based on ultrasound imaging) crossed-matched with 50 individuals without NAFLD based on age, sex and body mass index. Bone mineral density, serum calcium and phosphorus levels, serum parathyroid hormone, serum vitamin D and fasting insulin level were assessed. Osteoporosis was prevalent in NAFLD patients versus to controls (19/50 vs. 0/50; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). There was significant decrease in bone mineral density in NAFLD patients than controls (&#8722;&#8201;2.29&#8201;&#177;&#8201;0.4 vs. &#8722;&#8201;1.53&#8201;&#177;&#8201;0.1; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). There was a statistical significance decrease in serum vitamin D and calcium levels in NAFLD patients than controls. Furthermore, vitamin D levels in the NAFLD group was a predictor for osteoporosis (OR 0.614; 95% CI 0.348&#8211;0.825). Patients with NAFLD tend to have a significant decrease in bone density, vitamin D, and serum calcium levels than controls.
</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Gastroenterology</kwd><kwd>Rheumatology</kwd></kwd-group><funding-group><award-group><funding-source><institution>The Science, Technology &amp; Innovation Funding Authority (STDF OA Agreement)</institution></funding-source></award-group><open-access><p>Open access funding provided by The Science, Technology &amp; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Nonalcoholic fatty liver disease (NAFLD) has emerged as noninfectious liver disease affecting between 17 and 33% in the general population and 75% in obese and/or diabetic individuals worldwide<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. NAFLD is not confined to adult but it occurs in children and adolescents. Prevalence report from Egypt estimates NAFLD among school children was 15.8% in cross-sectional study<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>.</p><p id="Par3">The pathological spectrum of NAFLD ranges from simple steatosis to nonalcoholic steatohepatitis (NASH) that ultimately may progress to fibrosis and cirrhosis which may be complicated by hepatocellular carcinoma<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref></sup>.</p><p id="Par4">NAFLD has been linked with extra hepatic diseases as cardiomyopathy, cardiac arrhythmias, chronic kidney disease, type 2 diabetes mellitus (T2DM) and obstructive sleep apnea<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup>. Moreover, NAFLD has been associated with increased risk of extra hepatic cancer including gastrointestinal, urinary, lung, breast, and gynecological cancers<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>.</p><p id="Par5">Osteoporosis (OP) is a systemic skeletal disease characterized by low bone mineral density (BMD) and may be associated with pathological fracture<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. In developed countries, OP affecting 9&#8211;38% of women and 1&#8211;8% of men aged&#8201;&gt;&#8201;50&#160;years<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>.</p><p id="Par6">Diagnosis of OP is based on dual-energy X-ray absorptiometry (DEXA)<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. There are multiple sites that could be used to assess bone mineral density including hip, spine and wrist. In spite of these multiple sites, DEXA scanning of the hip or spine is validated by world health organization (WHO)<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>.</p><p id="Par7">About 12&#8211;55% of patients with liver cirrhosis have imminent risk of vertebral fractures so patients with chronic liver disease need to be screened by DEXA scan for early detection of OP as vertebral fractures are usually asymptomatic<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup>.</p><p id="Par8">Several cross sectional studies have evaluated association between NAFLD and lower BMD. Unfortunately, the results of these studies were conflicting as some studies have identified a significant association between NAFLD and low BMD<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup> and other studies showed no significant associations between NAFLD and low BMD<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup>.</p><p id="Par9">Some Studies showed that NAFLD may contribute in the pathophysiology of bone demineralization and OP via production of multiple pro-inflammatory cytokines, tumor necrosis factor &#945; (TNF-&#945;), pro-oxidant mediators, bone-influencing molecules and/or via the direct effect on hepatic and insulin resistance<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>.</p><p id="Par10">As association between NAFLD and low BMD is still a matter of controversy, so the study aimed to evaluate bone mineral density, serum calcium and vitamin D in patients with NAFLD to determine if patients who have NAFLD are at risk of developing OP.</p></sec><sec id="Sec2"><title>Patients and methods</title><p id="Par11">This cross section study was done in Hepato-Gastroentrology and rheumatology departments, Al-Azhar Assiut University hospital, from February 2019 to December 2020 to determine if patients who have NAFLD are at risk of OP.</p><p id="Par12">A total 100 individuals were enrolled in the study; 50 patients diagnosed by ultrasound to have NAFLD and 50 crossed matched individuals without NAFLD based on age, sex and BMI.</p><p id="Par13">The study was approved by ethical committee of Al-Azhar Assiut faculty of medicine and an informed written consent was signed by every individual before being enrolled in the study. The study was conducted in accordance with ethical principles of the World Medical Association Declaration of Helsinki.</p><sec id="Sec3"><title>Inclusion criteria</title><p id="Par14">Any individual diagnosed by ultrasound to have (NAFLD) and aged&#8201;&#8805;&#8201;18&#160;years.</p></sec><sec id="Sec4"><title>Exclusion criteria</title><p id="Par15">Individual with any one of the following criteria were excluded from the study: (1) aged&#8201;&#8804;&#8201;18&#160;years, (2) any liver disease that could lead to NAFLD such as viral hepatitis, autoimmune liver diseases, alcohol consumption, Wilson&#8217;s disease, hemochromatosis, (3) recent exposure to hepatotoxic drugs within 6&#160;months or drugs containing or affecting vitamin D level, (4) diabetes mellitus, (5) renal disease (6) Pregnant or lactating women.</p></sec><sec id="Sec5"><title>Investigatory work-up</title><p id="Par16">Eligible individuals (cases and controls) were admitted to Hepato-Gastroentrology and rheumatology departments, et al.-Azhar Assiut University Hospital and full history taking, clinical examination and BMI were assessed for every individual.</p><p id="Par17">After midnight fasting, eligible individuals were assessed by the following laboratory tests and imaging studies: complete blood count (CBC), liver function tests (serum bilirubin, AST, ALT, albumin and INR), renal function test (urea, creatinine and serum uric acid), fasting blood sugar (FBS), cholesterol, triglycerides and erythrocyte sedimentation rate (ESR).</p><p id="Par18">Serum calcium and phosphorus levels were assessed by colorimetric method using (spinreact, S.A.U., Spain) and (5010 chemistry photometer, Germany) and reference range for serum calcium is 8.0&#8211;10.5&#160;mg/dl and 2.5&#8211;5&#160;mg/dl for phosphorus.</p><p id="Par19">Serum parathyroid hormone level was assessed by ELISA using (Human PTH ELISA Kit, Bioassay technology laboratory) produced by (Shanghai Korian Biotech Co., Ltd, China) and (Robonik ELISA plate reader, India).</p><p id="Par20">Serum 25-OH Vitamin D3/D2 level was assessed by ELISA using (ORGENTEC Diagnostika GmbH, Germany) and (Robonik ELISA plate reader, India).</p><p id="Par21">Fasting insulin level was assessed by ELISA using (human insulin enzyme immunoassay test Kit , prechek Bio Inc , USA) and (Robonik ELISA plate reader , India) and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) was calculated by using the following equation: HOMA-IR&#8201;=&#8201;fasting insulin (micro unite/ml)&#8201;&#215;&#8201;fasting blood glucose (mmol/ml)/22.5<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup>.</p><p id="Par22">Pelvi-abdominal ultrasound examination for eligible individuals was done after a midnight fasting using a B-mode convex probe US equipment (Esaote ID, CE0051; Technos, Genoa, Italy) with a 4.5&#8211;7&#160;MHz to assess severity of fatty liver and NAFLD was graded according to echogenicty of the liver<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> into Grade I: minimal diffuse increase in hepatic echogenicty in which the liver appears bright compared with the cortex of the kidney with normal visualization of diaphragm and borders of intrahepatic vessel, Grade II: moderate diffuse increase in hepatic echogenicty with slightly impaired visualization of diaphragm and intrahepatic vessels, Grade III: marked increase in hepatic echogenicty which obscures visualization of intrahepatic vessels and diaphragm.</p><p id="Par23">Bone mineral density (BMD) at lumbar spine was measured by dual energy X-ray absorptiometry (DEXA) (DEXA scan lunar DPX-NT 2013 made in USA by General Electric) and according to the World Health Organization (WHO) criteria for BMD, OP in adult is defined by a T score less than -2.5 and osteopenia is defined by a T score between &#8722;&#8201;1 and &#8722;&#8201;2.5<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR23">23</xref>&#8211;<xref ref-type="bibr" rid="CR25">25</xref></sup><bold><italic toggle="yes">.</italic></bold></p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par24">The statistical analysis was performed using Windows 10 SPSS version 22 (IBM SPSS Inc., Chicago, Illinois, USA)) program. Normally distributed data were presented as mean&#8201;&#177;&#8201;standard deviation (SD) and categorical data were expressed as number and percentage. The Student&#8217;s <italic toggle="yes">t</italic> test was performed for continuous variables and categorical variables were compared by the chi-square (&#967;2) and Fisher's exact tests. Regression analysis was done to predict the independent associated factors that may affect BMD in patients with NAFLD. <italic toggle="yes">P</italic> value of&#8201;&lt;&#8201;0.05 was considered as statistical significance.</p></sec></sec><sec id="Sec7"><title>Results</title><p id="Par25">A total of 100 individuals were included in the study. The baseline and laboratory characteristics of individuals with NAFLD (cases) and individuals without NAFLD (controls) is shown in (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Baseline and Laboratory characteristics of studied groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Parameters</th><th align="left" colspan="1" rowspan="1">Cases (N&#8201;=&#8201;50) Mean&#8201;&#177;&#8201;SD</th><th align="left" colspan="1" rowspan="1">Controls (N&#8201;=&#8201;50) Mean&#8201;&#177;&#8201;SD</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (years) Mean&#8201;+&#8201;standard deviation (SD)</td><td align="left" colspan="1" rowspan="1">45.40&#8201;&#177;&#8201;12.5</td><td align="left" colspan="1" rowspan="1">45.12&#8201;&#177;&#8201;11.5</td><td char="." align="char" colspan="1" rowspan="1">0.907</td></tr><tr><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">28 (56%)</td><td align="left" colspan="1" rowspan="1">30 (60%)</td><td char="." align="char" colspan="1" rowspan="1">0.420</td></tr><tr><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">22 (44%)</td><td align="left" colspan="1" rowspan="1">20 (40%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Nonsmoker</td><td align="left" colspan="1" rowspan="1">37 (74%)</td><td align="left" colspan="1" rowspan="1">38 (76%)</td><td char="." align="char" colspan="1" rowspan="1">0.817</td></tr><tr><td align="left" colspan="1" rowspan="1">Smoker</td><td align="left" colspan="1" rowspan="1">13 (26%)</td><td align="left" colspan="1" rowspan="1">12 (24%)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Body mass index(BMI)</td><td align="left" colspan="1" rowspan="1">27.85&#8201;&#177;&#8201;5.4</td><td align="left" colspan="1" rowspan="1">27.77&#8201;&#177;&#8201;5.5</td><td char="." align="char" colspan="1" rowspan="1">0.941</td></tr><tr><td align="left" colspan="1" rowspan="1">Hemoglobin concentration (g/dl)</td><td align="left" colspan="1" rowspan="1">12.79&#8201;&#177;&#8201;1.2</td><td align="left" colspan="1" rowspan="1">12.71&#8201;&#177;&#8201;1.3</td><td char="." align="char" colspan="1" rowspan="1">0.41</td></tr><tr><td align="left" colspan="1" rowspan="1">White blood cells *103/&#181;L</td><td align="left" colspan="1" rowspan="1">38.08&#8201;&#177;&#8201;10.6</td><td align="left" colspan="1" rowspan="1">36.09&#8201;&#177;&#8201;11.4</td><td char="." align="char" colspan="1" rowspan="1">0.37</td></tr><tr><td align="left" colspan="1" rowspan="1">Red blood cells (106/mm3)</td><td align="left" colspan="1" rowspan="1">4.91&#8201;&#177;&#8201;0.9</td><td align="left" colspan="1" rowspan="1">5.01&#8201;&#177;&#8201;1.0</td><td char="." align="char" colspan="1" rowspan="1">0.9</td></tr><tr><td align="left" colspan="1" rowspan="1">Platelet *103/&#181;L</td><td align="left" colspan="1" rowspan="1">270.91&#8201;&#177;&#8201;13.3</td><td align="left" colspan="1" rowspan="1">288.46&#8201;&#177;&#8201;16.2</td><td char="." align="char" colspan="1" rowspan="1">0.76</td></tr><tr><td align="left" colspan="1" rowspan="1">Mean corpuscular volume (M CV) (fl)</td><td align="left" colspan="1" rowspan="1">83.95&#8201;&#177;&#8201;9.0</td><td align="left" colspan="1" rowspan="1">83.78&#8201;&#177;&#8201;8.9</td><td char="." align="char" colspan="1" rowspan="1">0.072</td></tr><tr><td align="left" colspan="1" rowspan="1">Mean Corpuscular Haemoglobin (MCH) (pg)</td><td align="left" colspan="1" rowspan="1">28.43&#8201;&#177;&#8201;4.1</td><td align="left" colspan="1" rowspan="1">27.65&#8201;&#177;&#8201;1.8</td><td char="." align="char" colspan="1" rowspan="1">0.13</td></tr><tr><td align="left" colspan="1" rowspan="1">Triglycerides (mg/dl)</td><td align="left" colspan="1" rowspan="1">162.12&#8201;&#177;&#8201;12.3</td><td align="left" colspan="1" rowspan="1">163.66&#8201;&#177;&#8201;10.4</td><td char="." align="char" colspan="1" rowspan="1">0.929</td></tr><tr><td align="left" colspan="1" rowspan="1">Total cholesterol (mg/dl)</td><td align="left" colspan="1" rowspan="1">183.22&#8201;&#177;&#8201;8.4</td><td align="left" colspan="1" rowspan="1">176.64&#8201;&#177;&#8201;7.5</td><td char="." align="char" colspan="1" rowspan="1">0.560</td></tr><tr><td align="left" colspan="1" rowspan="1">Erythrocyte sedimentation rate (ESR) (mm/hr)</td><td align="left" colspan="1" rowspan="1">21.44&#8201;&#177;&#8201;1.8</td><td align="left" colspan="1" rowspan="1">22.60&#8201;&#177;&#8201;1.9</td><td char="." align="char" colspan="1" rowspan="1">0.661</td></tr><tr><td align="left" colspan="1" rowspan="1">Alanine transferase (IU/L)</td><td align="left" colspan="1" rowspan="1">31.52&#8201;&#177;&#8201;2.5</td><td align="left" colspan="1" rowspan="1">23.62&#8201;&#177;&#8201;1.4</td><td char="." align="char" colspan="1" rowspan="1">0.003</td></tr><tr><td align="left" colspan="1" rowspan="1">Aspartate transferase (AST) (IU/L)</td><td align="left" colspan="1" rowspan="1">30.58&#8201;&#177;&#8201;2.1</td><td align="left" colspan="1" rowspan="1">28.60&#8201;&#177;&#8201;2.3</td><td char="." align="char" colspan="1" rowspan="1">0.252</td></tr><tr><td align="left" colspan="1" rowspan="1">Albumin (g/L)</td><td align="left" colspan="1" rowspan="1">4.17&#8201;&#177;&#8201;0.5</td><td align="left" colspan="1" rowspan="1">4.15&#8201;&#177;&#8201;0.5</td><td char="." align="char" colspan="1" rowspan="1">0.868</td></tr><tr><td align="left" colspan="1" rowspan="1">Total Protein (g/dl)</td><td align="left" colspan="1" rowspan="1">7.17&#8201;&#177;&#8201;0.7</td><td align="left" colspan="1" rowspan="1">7.29&#8201;&#177;&#8201;0.7</td><td char="." align="char" colspan="1" rowspan="1">0.382</td></tr><tr><td align="left" colspan="1" rowspan="1">Total Bilirubin (mg/dl)</td><td align="left" colspan="1" rowspan="1">0.64&#8201;&#177;&#8201;0.1</td><td align="left" colspan="1" rowspan="1">0.65&#8201;&#177;&#8201;0.1</td><td char="." align="char" colspan="1" rowspan="1">0.929</td></tr><tr><td align="left" colspan="1" rowspan="1">Direct Bilirubin (mg/dl)</td><td align="left" colspan="1" rowspan="1">0.22&#8201;&#177;&#8201;0.1</td><td align="left" colspan="1" rowspan="1">0.21&#8201;&#177;&#8201;0.1</td><td char="." align="char" colspan="1" rowspan="1">0.820</td></tr><tr><td align="left" colspan="1" rowspan="1">International normalized ratio (INR)</td><td align="left" colspan="1" rowspan="1">1.10&#8201;&#177;&#8201;0.1</td><td align="left" colspan="1" rowspan="1">1.11&#8201;&#177;&#8201;0.2</td><td char="." align="char" colspan="1" rowspan="1">0.770</td></tr><tr><td align="left" colspan="1" rowspan="1">Urea (mg/dl)</td><td align="left" colspan="1" rowspan="1">34.22&#8201;&#177;&#8201;10.8</td><td align="left" colspan="1" rowspan="1">31.34&#8201;&#177;&#8201;10.5</td><td char="." align="char" colspan="1" rowspan="1">0.179</td></tr><tr><td align="left" colspan="1" rowspan="1">Creatinine (mg/dl)</td><td align="left" colspan="1" rowspan="1">0.90&#8201;&#177;&#8201;0.1</td><td align="left" colspan="1" rowspan="1">0.82&#8201;&#177;&#8201;0.1</td><td char="." align="char" colspan="1" rowspan="1">0.142</td></tr><tr><td align="left" colspan="1" rowspan="1">Fasting blood sugar (FBG) (mg/dl)</td><td align="left" colspan="1" rowspan="1">98.94&#8201;&#177;&#8201;16.3</td><td align="left" colspan="1" rowspan="1">97.14&#8201;&#177;&#8201;15.6</td><td char="." align="char" colspan="1" rowspan="1">0.589</td></tr><tr><td align="left" colspan="1" rowspan="1">Fasting Insulin (mIU/L)</td><td align="left" colspan="1" rowspan="1">4.50&#8201;&#177;&#8201;0.4</td><td align="left" colspan="1" rowspan="1">4.03&#8201;&#177;&#8201;0.3</td><td char="." align="char" colspan="1" rowspan="1">0.380</td></tr><tr><td align="left" colspan="1" rowspan="1">HOMA-IR, median (range)</td><td align="left" colspan="1" rowspan="1">0.96 (0.329&#8211;2.24)</td><td align="left" colspan="1" rowspan="1">0.827 (0.19&#8211;3.26)</td><td char="." align="char" colspan="1" rowspan="1">0.326</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">HOMA-IR</italic> homeostasis model assessment of insulin resistance.</p></table-wrap-foot></table-wrap></p><p id="Par26">Our study showed no significant difference between cases and controls regarding to age, sex, smoking, BMI and the baseline and laboratory characteristic of studied groups. Moreover, cases had elevated ALT more than controls with significant P-value 0.003 (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par27">Among 50 patients enrolled in the study, 41 (82%) patients had grade I fatty liver and 9 (18%) patients had grade <bold>&#8805;</bold> II (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Ultrasound characteristics of studied groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Parameters</th><th align="left" colspan="1" rowspan="1">Cases (N&#8201;=&#8201;50) Mean&#8201;&#177;&#8201;SD</th><th align="left" colspan="1" rowspan="1">Controls (N&#8201;=&#8201;50) Mean&#8201;&#177;&#8201;SD</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">US /Fatty liver grade 0</td><td char="(" align="char" colspan="1" rowspan="1">0 (0%)</td><td char="(" align="char" colspan="1" rowspan="1">50 (100%)</td><td align="left" rowspan="3" colspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">US /Fatty liver grade I</td><td char="(" align="char" colspan="1" rowspan="1">41 (82%)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">US /Fatty liver grade&#8201;&#8805;&#8201;II</td><td char="(" align="char" colspan="1" rowspan="1">9 (18%)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0%)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">US</italic> ultrasound.</p></table-wrap-foot></table-wrap></p><p id="Par28">As regarded to factors affecting bone density, the study showed a significant difference in PTH, vitamin D, and serum calcium between cases and controls group (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Factors affecting bone density among studied groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Factors affecting bone density</th><th align="left" colspan="1" rowspan="1">Cases (N&#8201;=&#8201;50) Mean&#8201;&#177;&#8201;SD</th><th align="left" colspan="1" rowspan="1">Controls (N&#8201;=&#8201;50) Mean&#8201;&#177;&#8201;SD</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">PTH (pg/ml)</td><td char="." align="char" colspan="1" rowspan="1">56.27&#8201;&#177;&#8201;7.8</td><td char="." align="char" colspan="1" rowspan="1">32.48&#8201;&#177;&#8201;9.1</td><td char="." align="char" colspan="1" rowspan="1">0.002</td></tr><tr><td align="left" colspan="1" rowspan="1">Vitamin D (ng/ml)</td><td char="." align="char" colspan="1" rowspan="1">28.94&#8201;&#177;&#8201;7.5</td><td char="." align="char" colspan="1" rowspan="1">61.50&#8201;&#177;&#8201;14.1</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Serum Ca (mg/dl)</td><td char="." align="char" colspan="1" rowspan="1">8.38&#8201;&#177;&#8201;0.6</td><td char="." align="char" colspan="1" rowspan="1">9.86&#8201;&#177;&#8201;0.7</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Serum P (mg/dl)</td><td char="." align="char" colspan="1" rowspan="1">4.74&#8201;&#177;&#8201;0.9</td><td char="." align="char" colspan="1" rowspan="1">4.87&#8201;&#177;&#8201;0.8</td><td char="." align="char" colspan="1" rowspan="1">&#8201;=&#8201;0.414</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">PTH</italic> parathyroid hormone, <italic toggle="yes">Ca</italic> calcium, <italic toggle="yes">P</italic> phosphorus.</p></table-wrap-foot></table-wrap></p><p id="Par29">DEXA scan results showed a significant difference between cases (&#8722;&#8201;2.29&#8201;&#177;&#8201;0.4) and controls (&#8722;&#8201;1.53&#8201;&#177;&#8201;0.1) with <italic toggle="yes">p</italic> value&#8201;&lt;&#8201;0.001 (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Dual energy X ray absorptiometry among studied groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Cases (N&#8201;=&#8201;50) Mean&#8201;&#177;&#8201;SD</th><th align="left" colspan="1" rowspan="1">Controls (N&#8201;=&#8201;50) Mean&#8201;&#177;&#8201;SD</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">&#8201;DEXA Scan (BMD) T-score</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;2.29&#8201;&#177;&#8201;0.4</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;1.53&#8201;&#177;&#8201;0.1</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">DEXA</italic> dual energy x-ray absorptiomet&#8201;ry.</p></table-wrap-foot></table-wrap></p><p id="Par30">Our results showed a significant difference in bone density between cases and controls. Moreover, OP was more prevalent in cases than controls group with <italic toggle="yes">p</italic> value&#8201;&lt;&#8201;0.001. Among the NAFLD group, 19 patients had OP (16 of them had grade I fatty liver and 3 of them had grade&#8201;&#8805;&#8201;II fatty liver), 28 patients had osteopenia (22 of them had grade I fatty liver and 6 had grade <bold>&#8805;&#8201;</bold>II fatty liver) 3 patients had normal bone density (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>).<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Relationship between degree of fatty liver and degree of bone density.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variable</th><th align="left" colspan="1" rowspan="1">Osteoporosis (n&#8201;=&#8201;19)</th><th align="left" colspan="1" rowspan="1">Osteopenia (n&#8201;=&#8201;68)</th><th align="left" colspan="1" rowspan="1">Normal (n&#8201;=&#8201;13)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Control</td><td char="." align="char" colspan="1" rowspan="1">0 (0%)</td><td char="." align="char" colspan="1" rowspan="1">40 (58.8%)</td><td char="." align="char" colspan="1" rowspan="1">10 (76.9%)</td><td char="." align="char" rowspan="2" colspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">NAFLD</td><td char="." align="char" colspan="1" rowspan="1">19 (100%)</td><td char="." align="char" colspan="1" rowspan="1">28 (41.2%)</td><td char="." align="char" colspan="1" rowspan="1">3 (23.1%)</td></tr><tr><td align="left" colspan="5" rowspan="1">Grade of fatty liver</td></tr><tr><td align="left" colspan="1" rowspan="1">0</td><td char="." align="char" colspan="1" rowspan="1">0 (0%)</td><td char="." align="char" colspan="1" rowspan="1">40 (58.8%)</td><td char="." align="char" colspan="1" rowspan="1">10 (76.9%)</td><td char="." align="char" rowspan="3" colspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">I</td><td char="." align="char" colspan="1" rowspan="1">16 (84.2%)</td><td char="." align="char" colspan="1" rowspan="1">22 (32.4%)</td><td char="." align="char" colspan="1" rowspan="1">3 (23.1%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8201;&gt;&#8201;I</td><td char="." align="char" colspan="1" rowspan="1">3 (15.8%)</td><td char="." align="char" colspan="1" rowspan="1">6 (8.8%)</td><td char="." align="char" colspan="1" rowspan="1">0 (0%)</td></tr></tbody></table></table-wrap></p><p id="Par31">In our study, we performed logistic regression model analysis to determine predictors of OP among the NAFLD group. We found among patients with NAFLD, serum vitamin D level was statistically significant predicts OP (OR 0.614; 95% CI 0.348&#8211;0.825) (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). Also female gender, BMI, bilirubin, serum calcium, serum phosphorus PTH, fasting insulin, and insulin resistance were statistically significant predictors of OP among the NAFLD group (Table&#160;<xref rid="Tab6" ref-type="table">6</xref>).<table-wrap id="Tab6" position="float" orientation="portrait"><label>Table 6</label><caption><p>Predictors of Osteoporosis among the NAFLD Sample: Logistic Regression Model.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Variable (per unit increase)</th><th align="left" colspan="2" rowspan="1">Univariate</th><th align="left" colspan="2" rowspan="1">Multivariate</th></tr><tr><th align="left" colspan="1" rowspan="1">OR (95% CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th><th align="left" colspan="1" rowspan="1">OR (95% CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age/years</td><td char="(" align="char" colspan="1" rowspan="1">1.023 (0.976&#8211;1.073)</td><td char="." align="char" colspan="1" rowspan="1">0.344</td><td char="(" align="char" colspan="1" rowspan="1">1.013 (0.981&#8211;1.062)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;=&#8201;0.547</td></tr><tr><td align="left" colspan="1" rowspan="1">Sex (Female)</td><td char="(" align="char" colspan="1" rowspan="1">3.600 (1.086&#8211;7.932)</td><td char="." align="char" colspan="1" rowspan="1">0.036</td><td char="(" align="char" colspan="1" rowspan="1">2.288 (1.147&#8211;6.655)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;=&#8201;0.018</td></tr><tr><td align="left" colspan="1" rowspan="1">Smoker</td><td char="(" align="char" colspan="1" rowspan="1">3.516 (1.102&#8211;9.446)</td><td char="." align="char" colspan="1" rowspan="1">0.021</td><td char="(" align="char" colspan="1" rowspan="1">3.057 (1.066&#8211;5.126)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;=&#8201;0.031</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI</td><td char="(" align="char" colspan="1" rowspan="1">1.185 (1.006&#8211;2.008)</td><td char="." align="char" colspan="1" rowspan="1">0.048</td><td char="(" align="char" colspan="1" rowspan="1">2.258 (1.287&#8211;4.916)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;=&#8201;0.040</td></tr><tr><td align="left" colspan="1" rowspan="1">Bilirubin (mg/dl)</td><td char="(" align="char" colspan="1" rowspan="1">2.521 (1.033&#8211;8.361)</td><td char="." align="char" colspan="1" rowspan="1">0.044</td><td char="." align="char" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Serum Ca (mg/dl)</td><td char="(" align="char" colspan="1" rowspan="1">0.549 (0.212&#8211;0.769)</td><td char="." align="char" colspan="1" rowspan="1">0.019</td><td char="(" align="char" colspan="1" rowspan="1">0.180 (0.043&#8211;0.756)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;=&#8201;0.019</td></tr><tr><td align="left" colspan="1" rowspan="1">Serum P (mg/dl)</td><td char="(" align="char" colspan="1" rowspan="1">0.893 (0.529&#8211;0.994)</td><td char="." align="char" colspan="1" rowspan="1">0.031</td><td char="(" align="char" colspan="1" rowspan="1">0.741 (0.425&#8211;0.921)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;=&#8201;0.044</td></tr><tr><td align="left" colspan="1" rowspan="1">PTH (pg/ml)</td><td char="(" align="char" colspan="1" rowspan="1">1.098 (1.008&#8211;1.120)</td><td char="." align="char" colspan="1" rowspan="1">0.041</td><td char="(" align="char" colspan="1" rowspan="1">1.020 (1.002&#8211;1.039)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;=&#8201;0.029</td></tr><tr><td align="left" colspan="1" rowspan="1">Fasting Insulin</td><td char="(" align="char" colspan="1" rowspan="1">1.313 (1.060&#8211;1.627)</td><td char="." align="char" colspan="1" rowspan="1">0.013</td><td char="(" align="char" colspan="1" rowspan="1">1.868 (1.218&#8211;2.866)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;=&#8201;0.004</td></tr><tr><td align="left" colspan="1" rowspan="1">HOMA-IR</td><td char="(" align="char" colspan="1" rowspan="1">3.056 (1.244&#8211;7.507)</td><td char="." align="char" colspan="1" rowspan="1">0.015</td><td char="." align="char" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Vit. D Level (ng/ml)</td><td char="(" align="char" colspan="1" rowspan="1">0.614 (0.348&#8211;0.825)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td><td char="(" align="char" colspan="1" rowspan="1">0.268 (0.018&#8211;0.446)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;=&#8201;0.011</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">OR</italic> odd ratio, <italic toggle="yes">CI</italic> confidence interval.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec8"><title>Discussion</title><p id="Par32">Large numbers of cross sectional studies have identified a significant association between NAFLD and low BMD, but this association remains a matter of controversy<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup>. One meta-analysis showed no significant difference in BMD between patients with NAFLD and controls<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Another meta-analysis showed NAFLD was associated with osteoporotic fracture, but not associated with low BMD<sup><xref ref-type="bibr" rid="CR27">27</xref></sup><bold><italic toggle="yes">.</italic></bold> However, recent meta-analysis done by Mantovani et al. found that NAFLD was significantly associated with low BMD in children and adolescents<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>.</p><p id="Par33">Our study showed a significant difference in bone density between patients with NAFLD and controls. Our results agree with Xia et al. who found that patients with NAFLD were significantly associated with low BMD<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Lee et al. reported a positive association between NAFLD and lumbar spine BMD in postmenopausal females<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Moreover, in Shen et al. cohort study showed that males and females patients with NAFLD were associated with increased risk of low BMD<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>.</p><p id="Par34">Our results showed that osteoporosis was more prevalent in patients with NAFLD compared to controls with <italic toggle="yes">p</italic> value&#8201;&lt;&#8201;0.001. Moreover among NAFLD group, 19 patients had osteoporosis and 28 patients had osteopenia. Our result is supported by meta-analysis study done by Pan et al.<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> who reported that prevalence and risk of OP or osteoporotic fracture was significantly associated with NAFLD group than in controls. Also, Loosen et al.<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> reported that incidence of OP was significantly higher in the NAFLD patients (6.4%) compared to controls (5.1%) with <italic toggle="yes">p</italic> value&#8201;&lt;&#8201;0.001). Moreover, our study agrees with Pirgon et al.<sup><xref ref-type="bibr" rid="CR33">33</xref></sup> who indicated that NAFLD has a noxious effect on BMD in adolescents and was correlated with increased insulin resistance. Another cohort study performed by Chen et al.<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> showed increase risk of OP 1.35 times in patients with NAFLD than individuals without NAFLD. Also Li et al.<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> showed that NAFLD was significantly associated with history of osteoporotic fractures in middle-aged and elderly Chinese men.</p><p id="Par35">Our results can be interpreted in light that factors affecting bone mineral density including serum vitamin D and serum calcium were significantly lower in our studied patients with NAFLD than controls. Our results agree with Targher et al. who reported a potential link between decreased serum vitamin D and low BMD in patients with NAFLD<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Moreover, many studies proved that patients with NAFLD have lower levels of serum vitamin D than controls which lead to decrease BMD and increase risk of fractures<sup><xref ref-type="bibr" rid="CR35">35</xref>&#8211;<xref ref-type="bibr" rid="CR38">38</xref></sup>. Our study showed that patients with NAFLD had increased level of PTH compared to controls which indicates that patients with NAFLD had low BMD and OP.</p><p id="Par36">The association between hypovitaminosis D and NAFLD have been found in many diseases such as metabolic syndrome and obesity<sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup>. But in observational studies like our study, it is difficult to judge if NAFLD is a cause or result to hypovitaminosis D. Moreover, association between hypovitaminosis D and NAFLD could be accidental without actual relations between them. Consequently, the relationship between hypovitaminosis D and NAFLD needs prospective randomized controlled trials to compare development of NAFLD in patients with hypovitaminosis D versus healthy subjects and to assess effect of vitamin D supplementation on regression of NAFLD.</p><p id="Par37">In our study, we have performed logistic regression model analysis to determine predictors of osteoporosis among patients with NAFLD. We found that serum vitamin D levels was a statistically significant predictor for OP among NAFLD patients (OR 0.614; 95% CI 0.348&#8211;0.825) (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001).</p><p id="Par38">Insulin resistance is considerable risk factor for NAFLD<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR41">41</xref></sup> and insulin resistance and high fasting serum insulin may be associated with increased risk of low BMD<sup><xref ref-type="bibr" rid="CR42">42</xref></sup><bold><italic toggle="yes">.</italic></bold></p><p id="Par39">Although most people with NAFLD have metabolic dysfunction such as diabetes mellitus, but we excluded diabetic patients as diabetes mellitus deteriorates bone strength and increase susceptibility to bone fracture and this could affect results of our study<sup><xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup>.</p><p id="Par40">In our study, 10 patients had HOMA-IR more than 2, nine of them had decreased BMD (osteoporosis and osteopenia) and only one patient had significant insulin resistant (HOMA-IR more than 2.7). The patient who had HOMA-IR more than 2.7 also had osteopenia.</p><p id="Par41">In our study logistic regression model analysis showed that fasting insulin and insulin resistance were statistical significant predictors of OP among the NAFLD group. Our result agrees Filip et al.<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> who found that patients with NAFLD are associated with insulin resistance which is risk factors for low BMD.</p></sec><sec id="Sec9"><title>Conclusion</title><p id="Par42">Our study showed significant decreased in bone density and osteoporosis in patients with NAFLD compared to controls. Also serum vitamin D and serum calcium were significantly deceased in patients with NAFLD while level of PTH was increased in patients with NAFLD than controls which indicate that patients with NAFLD have potential risk of developing low BMD and OP. Additional further prospective studies are needed to determine the relationship between NAFLD and risk of low BMD and OP.</p><sec id="Sec10"><title>Study limitations and future recommendations</title><p id="Par43">This study had some limitations. The first limitation was the small sample size so we recommend further studies with large sample size with different risk factors to determine the relationship between NAFLD and the risk of low BMD and osteoporosis. Second, ultrasound had been used to determine whether individuals had NAFLD or not and its degrees, instead of liver biopsy which is the gold standard in diagnosis of fatty liver. Third, minimal steatosis (NAFLD grade 1) might be missed by using ultrasound. Fourth, further studies are recommended to screen BMD in patients with NAFLD who have diabetes mellitus as most patients with NAFLD have metabolic dysfunction as diabetes mellitus or insulin resistance. Moreover, in this study we screened only lumbar spine to detect BMD in patients with NAFLD and individuals without NAFLD and we recommend further studies for screening BMD of other vulnerable sites of fracture such as neck of the femur.</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher's note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>H.A.M. create the research idea. H.A.M. and A.-G.M. designed the study. H.A.M., A.-G.M., S.M.Z., and H.M.A., A.T.M., perform the clinical examination. A.M.M., E.S.S., A.W.E. performed the laboratory analysis. M.T.M. performed the ultrasound examination. S.M.Z. and A.-A.T.M. performed the DEXA scan analysis. H.A.M., A.-G.M., S.M.Z., and H.M.A., A.T.M., A.M.M., E.S.S., A.W.E., M.T.M., Q.M.K., and K.E.M. shared in analyzing and interpreting the patient data and in writing the manuscript drafting. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by The Science, Technology &amp; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Regarding to the datasets used and/or analyzed during the current study, the datasets used and/or analyzed will be available from the corresponding author on reasonable request.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par44">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Federico</surname><given-names>A</given-names></name><name name-style="western"><surname>Dallio</surname><given-names>M</given-names></name><name name-style="western"><surname>Masarone</surname><given-names>M</given-names></name><name name-style="western"><surname>Persico</surname><given-names>M</given-names></name><name name-style="western"><surname>Loguercio</surname><given-names>C</given-names></name></person-group><article-title>The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: Role of endothelial dysfunction</article-title><source>Eur. Rev. Med. Pharmacol. Sci.</source><year>2016</year><volume>20</volume><fpage>4731</fpage><lpage>4741</lpage><pub-id pub-id-type="pmid">27906428</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alkassabany</surname><given-names>YM</given-names></name><name name-style="western"><surname>Farghaly</surname><given-names>AG</given-names></name><name name-style="western"><surname>El-Ghitany</surname><given-names>EM</given-names></name></person-group><article-title>Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: A hospital-based study in Alexandria, Egypt</article-title><source>Arab. J. Gastroenterol.</source><year>2014</year><volume>15</volume><fpage>76</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.ajg.2014.05.002</pub-id><pub-id pub-id-type="pmid">25097051</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>VanWagner</surname><given-names>LB</given-names></name><name name-style="western"><surname>Rinella</surname><given-names>ME</given-names></name></person-group><article-title>Extrahepatic manifestations of nonalcoholic fatty liver disease</article-title><source>Curr. Hepatol. Rep.</source><year>2016</year><volume>15</volume><fpage>75</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1007/s11901-016-0295-9</pub-id><pub-id pub-id-type="pmid">27218012</pub-id><pub-id pub-id-type="pmcid">PMC4874648</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Pan, B., Yan, J., Zhao, P., Liu, J., Fu, S. Relationship between nonalcoholic fatty liver disease and bone mineral density in type 2 diabetic patients. <italic toggle="yes">Int. J. Diabetes Dev. Ctries</italic> (2021).</mixed-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>AA</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>A</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D</given-names></name></person-group><article-title>Extrahepatic manifestations of nonalcoholic fatty liver disease</article-title><source>Gut Liver</source><year>2020</year><volume>14</volume><issue>2</issue><fpage>168</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.5009/gnl19069</pub-id><pub-id pub-id-type="pmid">31195434</pub-id><pub-id pub-id-type="pmcid">PMC7096231</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>GE</given-names></name><name name-style="western"><surname>Cho</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Nonalcoholic fatty liver disease is associated with the development of obstructive sleep apnea</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>13473</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-92703-0</pub-id><pub-id pub-id-type="pmid">34188101</pub-id><pub-id pub-id-type="pmcid">PMC8241839</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name><name name-style="western"><surname>Petracca</surname><given-names>G</given-names></name><name name-style="western"><surname>Beatrice</surname><given-names>G</given-names></name><name name-style="western"><surname>Csermely</surname><given-names>A</given-names></name><name name-style="western"><surname>Herbert Tilg</surname><given-names>H</given-names></name><etal/></person-group><article-title>Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies</article-title><source>Gut</source><year>2022</year><volume>71</volume><issue>4</issue><fpage>778</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2021-324191</pub-id><pub-id pub-id-type="pmid">33685968</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cosman</surname><given-names>F</given-names></name><name name-style="western"><surname>de Beur</surname><given-names>SJ</given-names></name><name name-style="western"><surname>LeBoff</surname><given-names>MS</given-names></name><name name-style="western"><surname>Lewiecki</surname><given-names>EM</given-names></name><name name-style="western"><surname>Tanner</surname><given-names>B</given-names></name><name name-style="western"><surname>Randall</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinician&#8217;s guide to prevention and treatment of osteoporosis</article-title><source>Osteoporos. Int.</source><year>2014</year><volume>25</volume><issue>10</issue><fpage>2359</fpage><lpage>2381</lpage><pub-id pub-id-type="doi">10.1007/s00198-014-2794-2</pub-id><pub-id pub-id-type="pmid">25182228</pub-id><pub-id pub-id-type="pmcid">PMC4176573</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wade</surname><given-names>SW</given-names></name><name name-style="western"><surname>Strader</surname><given-names>C</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>LA</given-names></name><name name-style="western"><surname>Anthony</surname><given-names>MS</given-names></name><name name-style="western"><surname>O&#8217;Malley</surname><given-names>CD</given-names></name></person-group><article-title>Estimating prevalence of osteoporosis: Examples from industrialized countries</article-title><source>Arch Osteoporos.</source><year>2014</year><volume>9</volume><issue>1</issue><fpage>182</fpage><pub-id pub-id-type="doi">10.1007/s11657-014-0182-3</pub-id><pub-id pub-id-type="pmid">24847682</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filip</surname><given-names>R</given-names></name><name name-style="western"><surname>Radzki</surname><given-names>RP</given-names></name><name name-style="western"><surname>Bie&#324;ko</surname><given-names>M</given-names></name></person-group><article-title>Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis</article-title><source>Clin. Interv. Aging</source><year>2018</year><volume>13</volume><fpage>1879</fpage><lpage>1891</lpage><pub-id pub-id-type="doi">10.2147/CIA.S170533</pub-id><pub-id pub-id-type="pmid">30323574</pub-id><pub-id pub-id-type="pmcid">PMC6174895</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Premkumar</surname><given-names>K</given-names></name><name name-style="western"><surname>Narayanasamy</surname><given-names>K</given-names></name><name name-style="western"><surname>Jasmine</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Bone mineral density assessment in chronic liver disease</article-title><source>Arch Can. Res.</source><year>2017</year><volume>5</volume><fpage>1</fpage></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guanabens</surname><given-names>N</given-names></name><name name-style="western"><surname>Pares</surname><given-names>A</given-names></name></person-group><article-title>Osteoporosis in chronic liver disease</article-title><source>Liver Int.</source><year>2017</year><volume>38</volume><fpage>776</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1111/liv.13730</pub-id><pub-id pub-id-type="pmid">29479832</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collier</surname><given-names>J</given-names></name></person-group><article-title>Bone disorders in chronic liver disease</article-title><source>Hepatology</source><year>2007</year><volume>46</volume><fpage>1271</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1002/hep.21852</pub-id><pub-id pub-id-type="pmid">17886334</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhai</surname><given-names>T</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Jia</surname><given-names>X</given-names></name><name name-style="western"><surname>Xia</surname><given-names>P</given-names></name></person-group><article-title>Prevalence and trends in low bone density, osteopenia and osteoporosis in U.S. adults with non-alcoholic fatty liver disease, 2005&#8211;2014</article-title><source>Front. Endocrinol.</source><year>2022</year><volume>12</volume><fpage>825448</fpage><pub-id pub-id-type="doi">10.3389/fendo.2021.825448</pub-id><pub-id pub-id-type="pmcid">PMC8807487</pub-id><pub-id pub-id-type="pmid">35126317</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Cui, R., Sheng, H., Rui, X. F., Cheng, X. Y., Sheng, C. J., Wang, J. Y., <italic toggle="yes">et al</italic>. Low bone mineral density in Chinese adults with nonalcoholic fatty liver disease. <italic toggle="yes">Int. J. Endocrinol</italic>. 396545 (2013).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2013/396545</pub-id><pub-id pub-id-type="pmcid">PMC3747470</pub-id><pub-id pub-id-type="pmid">23983685</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dai</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Bi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ning</surname><given-names>G</given-names></name></person-group><article-title>Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2012</year><volume>97</volume><fpage>2033</fpage><lpage>2038</lpage><pub-id pub-id-type="doi">10.1210/jc.2011-3010</pub-id><pub-id pub-id-type="pmid">22466338</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name><name name-style="western"><surname>Yun</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SH</given-names></name><name name-style="western"><surname>Seo</surname><given-names>YG</given-names></name><name name-style="western"><surname>Min</surname><given-names>H</given-names></name><name name-style="western"><surname>Chung</surname><given-names>E</given-names></name><etal/></person-group><article-title>Association between bone mineral density and nonalcoholic fatty liver disease in Korean adults</article-title><source>J. Endocrinol. Invest.</source><year>2012</year><volume>39</volume><issue>11</issue><fpage>1329</fpage><lpage>1336</lpage><pub-id pub-id-type="doi">10.1007/s40618-016-0528-3</pub-id><pub-id pub-id-type="pmid">27561910</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaya</surname><given-names>M</given-names></name><name name-style="western"><surname>Isik</surname><given-names>D</given-names></name><name name-style="western"><surname>Bestas</surname><given-names>R</given-names></name><name name-style="western"><surname>Evliyaoglu</surname><given-names>O</given-names></name><name name-style="western"><surname>Akpolat</surname><given-names>V</given-names></name><name name-style="western"><surname>Buyukbayram</surname><given-names>H</given-names></name><etal/></person-group><article-title>Increased bone mineral density in patients with non-alcoholic steatohepatitis</article-title><source>World J. Hepatol.</source><year>2013</year><volume>5</volume><issue>11</issue><fpage>627</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.4254/wjh.v5.i11.627</pub-id><pub-id pub-id-type="pmid">24303091</pub-id><pub-id pub-id-type="pmcid">PMC3847946</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Targher</surname><given-names>G</given-names></name><name name-style="western"><surname>Lonardo</surname><given-names>A</given-names></name><name name-style="western"><surname>Rossini</surname><given-names>M</given-names></name></person-group><article-title>nonalcoholic fatty liver disease and decreased bone mineral density: Is there a link?</article-title><source>J. Endocrinol. Invest.</source><year>2015</year><volume>38</volume><fpage>817</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1007/s40618-015-0315-6</pub-id><pub-id pub-id-type="pmid">26003827</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muniyappa</surname><given-names>R</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Quon</surname><given-names>MJ</given-names></name></person-group><article-title>Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage</article-title><source>Am. J. Physiol.-Endocrinol. Metab.</source><year>2008</year><volume>294</volume><issue>1</issue><fpage>E15</fpage><lpage>E26</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00645.2007</pub-id><pub-id pub-id-type="pmid">17957034</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyer</surname><given-names>C</given-names></name><name name-style="western"><surname>Pimenta</surname><given-names>W</given-names></name><name name-style="western"><surname>Woerle</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Van Haeften</surname><given-names>T</given-names></name><name name-style="western"><surname>Szoke</surname><given-names>E</given-names></name><name name-style="western"><surname>Mitrakou</surname><given-names>A</given-names></name><etal/></person-group><article-title>Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><issue>8</issue><fpage>190914</fpage><pub-id pub-id-type="doi">10.2337/dc06-0438</pub-id><pub-id pub-id-type="pmid">16873801</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saadeh</surname><given-names>S</given-names></name><name name-style="western"><surname>Younossi</surname><given-names>ZM</given-names></name><name name-style="western"><surname>Remer</surname><given-names>EM</given-names></name><name name-style="western"><surname>Gramlich</surname><given-names>T</given-names></name><name name-style="western"><surname>Ong</surname><given-names>JP</given-names></name><name name-style="western"><surname>Hurley</surname><given-names>M</given-names></name><etal/></person-group><article-title>The utility of radiological imaging in nonalcoholic fatty liver disease</article-title><source>Gastroenterology</source><year>2002</year><volume>123</volume><fpage>745</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1053/gast.2002.35354</pub-id><pub-id pub-id-type="pmid">12198701</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H</given-names></name><name name-style="western"><surname>Chang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Association between non-alcoholic fatty liver disease-associated hepatic fibrosis and bone mineral density in postmenopausal women with type 2 diabetes or impaired glucose regulation</article-title><source>BMJ Open Diabetes Res. Care</source><year>2020</year><volume>8</volume><fpage>e000999</fpage><pub-id pub-id-type="doi">10.1136/bmjdrc-2019-000999</pub-id><pub-id pub-id-type="pmid">32759166</pub-id><pub-id pub-id-type="pmcid">PMC7409963</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uziel</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zifman</surname><given-names>E</given-names></name><name name-style="western"><surname>Hashkes</surname><given-names>PJ</given-names></name></person-group><article-title>Osteoporosis in children: pediatric and pediatric rheumatology perspective: A review</article-title><source>Pediatr. Rheumatol.</source><year>2020</year><volume>7</volume><issue>16</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1546-0096-7-16</pub-id><pub-id pub-id-type="pmcid">PMC2768686</pub-id><pub-id pub-id-type="pmid">19835571</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">The International Society for Clinical Densitometry. <italic toggle="yes">ISCD official positions: Adult [Internet]</italic>. The International Society for Clinical Densitometry (2013).</mixed-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Upala</surname><given-names>S</given-names></name><name name-style="western"><surname>Jaruvongvanich</surname><given-names>V</given-names></name><name name-style="western"><surname>Wijarnpreecha</surname><given-names>K</given-names></name><name name-style="western"><surname>Sanguankeo</surname><given-names>A</given-names></name></person-group><article-title>Nonalcoholic fatty liver disease and osteoporosis: A systematic review and metaanalysis</article-title><source>J. Bone Miner. Metab.</source><year>2017</year><volume>35</volume><fpage>685</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1007/s00774-016-0807-2</pub-id><pub-id pub-id-type="pmid">27928661</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name><name name-style="western"><surname>Dauriz</surname><given-names>M</given-names></name><name name-style="western"><surname>Gatti</surname><given-names>D</given-names></name><name name-style="western"><surname>Viapiana</surname><given-names>O</given-names></name><name name-style="western"><surname>Zoppini</surname><given-names>G</given-names></name><name name-style="western"><surname>Lippi</surname><given-names>G</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>CD</given-names></name><name name-style="western"><surname>Bonnet</surname><given-names>F</given-names></name><name name-style="western"><surname>Bonora</surname><given-names>E</given-names></name><name name-style="western"><surname>Targher</surname><given-names>G</given-names></name></person-group><article-title>Systematic review with meta-analysis: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density</article-title><source>Aliment. Pharmacol. Ther.</source><year>2019</year><volume>49</volume><fpage>375</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1111/apt.15087</pub-id><pub-id pub-id-type="pmid">30600540</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name><name name-style="western"><surname>Gatti</surname><given-names>D</given-names></name><name name-style="western"><surname>Zoppini</surname><given-names>G</given-names></name><name name-style="western"><surname>Lippi</surname><given-names>G</given-names></name><name name-style="western"><surname>Bonora</surname><given-names>E</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>CD</given-names></name><name name-style="western"><surname>Nobili</surname><given-names>V</given-names></name><name name-style="western"><surname>Targher</surname><given-names>G</given-names></name></person-group><article-title>Association between nonalcoholic fatty liver disease and reduced bone mineral density in children: a meta-analysis</article-title><source>Hepatology</source><year>2019</year><volume>70</volume><fpage>812</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1002/hep.30538</pub-id><pub-id pub-id-type="pmid">30706504</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>MF</given-names></name><name name-style="western"><surname>Lin</surname><given-names>HD</given-names></name><name name-style="western"><surname>Yan</surname><given-names>HM</given-names></name><name name-style="western"><surname>Bian</surname><given-names>H</given-names></name><name name-style="western"><surname>Chang</surname><given-names>XX</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>LS</given-names></name><etal/></person-group><article-title>The association of liver fat content and serum alanine aminotransferase with bone mineral density in middle-aged and elderly Chinese men and postmenopausal women</article-title><source>J. Transl. Med.</source><year>2016</year><volume>14</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/s12967-016-0766-3</pub-id><pub-id pub-id-type="pmid">26791408</pub-id><pub-id pub-id-type="pmcid">PMC4721203</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cen</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C</given-names></name></person-group><article-title>Increased risk of low bone mineral density in patients with non-alcoholic fatty liver disease: a cohort study</article-title><source>Eur. J. Endocrinol.</source><year>2020</year><volume>182</volume><fpage>157</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1530/EJE-19-0699</pub-id><pub-id pub-id-type="pmid">31770104</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>B</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Relationship between prevalence and risk of osteoporosis or osteoporotic fracture with non-alcoholic fatty liver disease: A systematic review and meta-analysis</article-title><source>Osteoporos. Int.</source><year>2022</year><volume>33</volume><fpage>2275</fpage><lpage>2286</lpage><pub-id pub-id-type="doi">10.1007/s00198-022-06459-y</pub-id><pub-id pub-id-type="pmid">35764892</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loosen</surname><given-names>SH</given-names></name><name name-style="western"><surname>Roderburg</surname><given-names>C</given-names></name><name name-style="western"><surname>Demir</surname><given-names>M</given-names></name><name name-style="western"><surname>Qvartskhava</surname><given-names>N</given-names></name><name name-style="western"><surname>Keitel</surname><given-names>V</given-names></name><etal/></person-group><article-title>Non-alcoholic fatty liver disease is associated with increased incidence of osteoporosis and bone fracture</article-title><source>Z. Gastroenterol.</source><year>2022</year><volume>60</volume><issue>08</issue><fpage>1221</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1055/a-1482-9236</pub-id><pub-id pub-id-type="pmid">34710938</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pirgon</surname><given-names>O</given-names></name><name name-style="western"><surname>Bilgin</surname><given-names>H</given-names></name><name name-style="western"><surname>Tolu</surname><given-names>I</given-names></name><name name-style="western"><surname>Odabas</surname><given-names>D</given-names></name></person-group><article-title>Correlation of insulin sensitivity with bone mineral status in obese adolescents with nonalcoholic fatty liver disease</article-title><source>Clin. Endocrinol.</source><year>2020</year><volume>75</volume><fpage>189</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2265.2011.04038.x</pub-id><pub-id pub-id-type="pmid">21521307</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Hsueh</surname><given-names>K</given-names></name><name name-style="western"><surname>Shen</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Increased risk of osteoporosis in patients with nonalcoholic fatty liver disease: A population-based retrospective cohort study</article-title><source>Medicine</source><year>2018</year><volume>97</volume><fpage>e12835</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000012835</pub-id><pub-id pub-id-type="pmid">30334985</pub-id><pub-id pub-id-type="pmcid">PMC6211874</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lips</surname><given-names>P</given-names></name></person-group><article-title>Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications</article-title><source>Endocr. Rev.</source><year>2001</year><volume>22</volume><issue>4</issue><fpage>477</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1210/edrv.22.4.0437</pub-id><pub-id pub-id-type="pmid">11493580</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shawky</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>AM</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>AQ</given-names></name><name name-style="western"><surname>Oraby</surname><given-names>MI</given-names></name></person-group><article-title>Vitamin D levels in egyptian patients with non-alcoholic fatty liver disease</article-title><source>J. Gastroenterol. Hepatol. Res.</source><year>2018</year><volume>7</volume><issue>1</issue><fpage>2530</fpage><lpage>2534</lpage><pub-id pub-id-type="doi">10.17554/j.issn.2224-3992.2018.07.745</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qin</surname><given-names>G</given-names></name></person-group><article-title>Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Results from a meta-analysis</article-title><source>Int. J. Clin. Exp. Med.</source><year>2015</year><volume>8</volume><fpage>17221</fpage><lpage>17234</lpage><pub-id pub-id-type="pmid">26770315</pub-id><pub-id pub-id-type="pmcid">PMC4694215</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eliades</surname><given-names>M</given-names></name><name name-style="western"><surname>Spyrou</surname><given-names>E</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>N</given-names></name><etal/></person-group><article-title>Meta-analysis: Vitamin D and non-alcoholic fatty liver disease</article-title><source>Aliment. Pharmacol. Ther.</source><year>2013</year><volume>38</volume><issue>3</issue><fpage>246</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1111/apt.12377</pub-id><pub-id pub-id-type="pmid">23786213</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Black</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Jacoby</surname><given-names>P</given-names></name><name name-style="western"><surname>She Ping-Delfos</surname><given-names>WC</given-names></name><name name-style="western"><surname>Mori</surname><given-names>TA</given-names></name><name name-style="western"><surname>Beilin</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Low serum 25-hydroxyvitamin D concentrations associate with nonalcoholic fatty liver disease in adolescents independent of adiposity</article-title><source>J. Gastroenterol. Hepatol.</source><year>2014</year><volume>29</volume><fpage>1215</fpage><lpage>1222</lpage><pub-id pub-id-type="doi">10.1111/jgh.12541</pub-id><pub-id pub-id-type="pmid">24611991</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>KC</given-names></name><name name-style="western"><surname>Hung</surname><given-names>HF</given-names></name><name name-style="western"><surname>Lu</surname><given-names>CW</given-names></name><name name-style="western"><surname>Chang</surname><given-names>HH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>LT</given-names></name><name name-style="western"><surname>Huang</surname><given-names>KC</given-names></name></person-group><article-title>Association of non-alcoholic fatty liver disease with metabolic syndrome independently of central obesity and insulin resistance</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>27034</fpage><pub-id pub-id-type="doi">10.1038/srep27034</pub-id><pub-id pub-id-type="pmid">27246655</pub-id><pub-id pub-id-type="pmcid">PMC4887873</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaggini</surname><given-names>M</given-names></name><name name-style="western"><surname>Morelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Buzzigoli</surname><given-names>E</given-names></name><name name-style="western"><surname>DeFronzo</surname><given-names>RA</given-names></name><name name-style="western"><surname>Bugianesi</surname><given-names>E</given-names></name><name name-style="western"><surname>Gastaldelli</surname><given-names>A</given-names></name></person-group><article-title>Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease</article-title><source>Nutrients</source><year>2013</year><volume>5</volume><fpage>1544</fpage><lpage>1560</lpage><pub-id pub-id-type="doi">10.3390/nu5051544</pub-id><pub-id pub-id-type="pmid">23666091</pub-id><pub-id pub-id-type="pmcid">PMC3708335</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>D</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K</given-names></name><name name-style="western"><surname>Park</surname><given-names>SM</given-names></name></person-group><article-title>Association between insulin resistance and bone mass in men</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2014</year><volume>99</volume><fpage>988</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1210/jc.2013-3338</pub-id><pub-id pub-id-type="pmid">24423302</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farr</surname><given-names>JN</given-names></name><name name-style="western"><surname>Khosla</surname><given-names>S</given-names></name></person-group><article-title>Determinants of bone strength and quality in diabetes mellitus in humans</article-title><source>Bone</source><year>2016</year><volume>82</volume><fpage>28</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2015.07.027</pub-id><pub-id pub-id-type="pmid">26211989</pub-id><pub-id pub-id-type="pmcid">PMC4679576</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wongdee</surname><given-names>K</given-names></name><name name-style="western"><surname>Charoenphandhu</surname><given-names>N</given-names></name></person-group><article-title>Osteoporosis in diabetes mellitus: Possible cellular and molecular mechanisms</article-title><source>World J. Diabetes</source><year>2011</year><volume>2</volume><issue>3</issue><fpage>41</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.4239/wjd.v2.i3.41</pub-id><pub-id pub-id-type="pmid">21537459</pub-id><pub-id pub-id-type="pmcid">PMC3083906</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>